The clinical use of biomarkers as prognostic factors in Ewing sarcoma

Overview

This review summarises the evidence on factors that predict outcome in Ewing sarcoma, with a focus on biological markers that could refine risk stratification beyond established clinical features. It is aimed at clinicians and researchers involved in sarcoma care and trial design.

Established clinical factors

The presence of metastatic disease at diagnosis remains the strongest adverse factor, with bone or bone-marrow involvement carrying a worse outlook than isolated lung metastases. Axial or pelvic primary site, large tumour volume and a poor histological response to initial chemotherapy are also linked to less favourable outcomes.

Molecular and genetic markers

The characteristic fusion gene confirms the diagnosis, but the specific fusion subtype has lost its prognostic value under modern treatment. Secondary genetic alterations, such as changes affecting cohesin-complex or tumour-suppressor genes, appear to identify more aggressive disease and are being studied as additional risk markers.

Circulating and emerging markers

Tumour-derived DNA in blood and detection of residual disease in bone marrow are promising tools for measuring disease burden and response to treatment, and for detecting relapse early. Their role in routine decision-making is not yet established.

Implications for practice

Treatment allocation is still based mainly on clinical factors. The authors call for prospective validation of biomarkers within clinical trials before they are used to intensify or reduce therapy.